Compare · JNJ vs JUNS
JNJ vs JUNS
Side-by-side comparison of Johnson & Johnson (JNJ) and Jupiter Neurosciences Inc. (JUNS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both JNJ and JUNS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $570.51B, about 67837.2x JUNS ($8.4M).
- Over the past year, JNJ is up 53.0% and JUNS is down 76.6% - JNJ leads by 129.5 points.
- JUNS has been more active in the news (26 items in the past 4 weeks vs 9 for JNJ).
- JNJ has more recent analyst coverage (25 ratings vs 0 for JUNS).
- Company
- Johnson & Johnson
- Jupiter Neurosciences Inc.
- Price
- $239.40+1.01%
- $0.22-3.98%
- Market cap
- $570.51B
- $8.4M
- 1M return
- +8.13%
- -39.25%
- 1Y return
- +52.97%
- -76.55%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2024
- News (4w)
- 9
- 26
- Recent ratings
- 25
- 0
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest JNJ
- Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial
- Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform
- Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
- Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
- RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
- New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
- FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage
- Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
- SEC Form SD filed by Johnson & Johnson
- SEC Form 13F-HR filed by Johnson & Johnson
Latest JUNS
- Presenting on Emerging Growth Conference 93 Day 2 on June 11; Register to live stream
- SEC Form PRE 14A filed by Jupiter Neurosciences Inc.
- Presenting on Emerging Growth Conference 93 Day 1 on June 10; Register to live stream
- SEC Form 424B3 filed by Jupiter Neurosciences Inc.
- Jupiter Neurosciences Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- SEC Form 4 filed by Director Brady Allison W
- SEC Form 4 filed by Chief Scientific Officer Hayward Marshall A.
- SEC Form 4 filed by Chief Financial Officer Elmasri Saleem
- SEC Form 4 filed by President and COO Silva Alison D.
- SEC Form 4 filed by Director Kampf Julie B.